A New Model for Communicating Risk Information in Direct-to-Consumer Print Advertisements

Abstract

Direct-to-consumer (DTC) pharmaceutical print ads are required by law to carry a “fair balance” of risks and benefits. There are little quantitative data on the effectiveness of risk communication to the consumer. A questionnaire-based method was used to compare consumer reactions to DTC print advertisements that varied in the amount and format of health risk information presented. The highest-scoring ads contained risk information in a prominent risk window. As the number of side effects listed (4, 8, or 12) increased, more consumers recalled no side effects correctly (37%, 45%, and 53%, respectively). On the basis of these results, communication of risk information to consumers could be improved by highlighting risks using a window format, and limiting the number of common side effects listed.

Keywords

Direct-to-consumer (DTC) advertising Risk information Communication Highlight section Brief Summary

Get full access to this article

View all access options for this article.

References

Aikin

Swasy

Braman

. Patient and physician attitudes and behaviors associated with DTC promotion of prescription drugs—Summary of FDA survey research results. 2004. Food and Drug Administration. Available at: http://www.fda.gov/cder/ddmac/Final%20Report/FRfinal111904.pdf. Accessed August 23, 2006.

Food and Drug Administration. Guidance for industry. Brief summary: Disclosing risk information in consumer-directed print advertisements, 2004. Available at: http://www.fda.gov/cber/gdlns/consumad.pdf. Accessed August 23, 2006.

Robinson

Hohmann

Rifkin

Direct-to-consumer pharmaceutical advertising: physician and public opinion and potential effects on the physician-patient relationship. Arch Intern Med. 2004;164:427–432.

Rosenthal

Berndt

Donohue

Frank

Epstein

. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346:498–505.

Berndt

. To inform or persuade? Direct-to-consumer advertising of prescription drugs. N Engl J Med. 2005;352:325–328.

Kessler

Berglund

Dernier

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.

Rosenbaum

Rubin

. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.

Rosenbaum

Rubin

. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516–524.

Woloshin

Schwartz

Welch

. The value of benefit data in direct-to-consumer drug ads. Health Affairs. April 28, 2004. Available at http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w4.234v1. Accessed August 23, 2006.

10.

The Henry J, Kaiser Family Foundation. Understanding the effects of direct-to-consumer prescription drug advertising. November 2001. Available at http://www.kff.org/rxdrugs/upload/Understanding-the-Effects-of-Direct-to-Consumer-Prescription-Drug-Advertising-Report.pdf. Accessed August 23, 2006.